Lorigerlimab clinical trials
Also written MGD019.
How each study uses lorigerlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lorigerlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2025 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 5
MacroGenics (4) · M.D. Anderson Cancer Center (4) · University of Miami (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test lorigerlimab.
- May 2027Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]Phase 2 · M.D. Anderson Cancer Center
- Jul 2027A Study of Lorigerlimab in Participants With Advanced Solid TumorsPhase 2 · MacroGenics
Studies
Open first, then newest update. How each study uses lorigerlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination DeficiencyRecruitingPhase 2University of MiamiNCT07565155Written as Lorigerlimab
- Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05475171Written as Lorigerlimab
- Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]RecruitingPhase 2M.D. Anderson Cancer CenterNCT07071961Written as Lorigerlimab
- A Study of Lorigerlimab in Participants With Advanced Solid TumorsRecruitingPhase 2MacroGenicsNCT06730347Written as Lorigerlimab
- A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerCompletedPhase 2MacroGenicsNCT05848011Written as lorigerlimab
- A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal CancerWithdrawnPhase 1/2M.D. Anderson Cancer CenterNCT07137390Written as Lorigerlimab
- A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal CancerWithdrawnPhase 2M.D. Anderson Cancer CenterNCT07223567Written as Lorigerlimab
- A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsCompletedPhase 1MacroGenicsNCT05293496Written as lorigerlimab
- MGD019 DART® Protein in Unresectable/Metastatic CancerCompletedPhase 1MacroGenicsNCT03761017Written as Lorigerlimab
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting1
Codes
What other systems call lorigerlimab · ClinicalTrials.gg INT016964
- UNII (FDA) JM802R57SALORIGERLIMABOne source FDA
- NCI Thesaurus C158505LorigerlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JM802R57SA | LORIGERLIMAB | One source FDA |
| NCI Thesaurus | C158505 | Lorigerlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.